24 Jul
2021

English courts will thrive in life sciences patent litigation alongside the UPC

The UK will remain a key venue for biopharma patent litigants even when the UPC is up and running, argues IAM life sciences editor Adam Houldsworth. In fact, the English courts may acquire a new strategic significance working in parallel with the new system

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth